# Bioheart

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bioheart-2

- Industry: Medical Devices & Equipment
- Headquarters: Shanghai, China
- Website: www.bio-heart.com
- Latest round: Series B (Dec 26, 2019)
- Investors on record: 4

## About

Established in 2014 and based in Shanghai, China, Bioheart is an innovative interventional cardiovascular company focuses on two therapies, bioresorbable scaffolds (BRS) and renal denervation (RDN), addressing the unmet medical needs of Chinese patients for the treatment of coronary and peripheral artery diseases and uncontrolled hypertension. The company has about 3000 square meters, including around 1800 square meters of class 10,000 clean workshops and a full-project testing laboratory for related products. The company has established a quality management system which meets the ISO13485/YY0287 standard. The company has gathered professionals in machinery, polymer, precision processing and clinical medicine with extensive experience in product design, quality control, clinical verification, and market development. In 2013, the company launched R&D of BRS product, and RDN product. In 2014, BRS product received interim reports from animal experiments, which preliminarily prove the safety and effectiveness of the products. In 2015, BRS products obtained product registration type inspection report. In 2019, BRS product completed the 3 years follow-up of the FIM clinical trial. Meanwhile, Iberis multi-electrode RDN system completed FIM clinical trial in Japan.

The company's products can be divided BRS products, RDN product, and other products. The BRS products include Bioheart BRS system, Bio-Leap below the knee, Bioheart ultra, and  Bio-Leap below the knee, Bioheart ultra both are in animal studies. The RDN product is Iberis generation RDN system, which complete confirmatory clinical trial in China,  feasibility clinical tral completed in China, and next step is to initiate confirmatory clinical trial. Other products has been in design stage.

The company plans to R&D and commercialization of core product, including confirmatory clinical trial, and registration fillings.

## Funding rounds

- Series B, Dec 26, 2019 — YuanBio Venture, CD Capital
- Series B, Oct 28, 2019 — Shanghai Zhangjiang Science & Technology Venture Capital, CD Capital, Qianhai Ark Capital

## Investors

- Shanghai Zhangjiang Science & Technology Venture Capital — Series B
- CD Capital — Series B
- Qianhai Ark Capital (https://capitalatlas.ai/funds/qianhai-ark-capital) — Series B
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series B